$Bob's and Jbem's Bitchin' Bios

[buckiii2]

NEW YORK, Sept. 29, 2016 /PRNewswire/ -- Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering. The completion of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Roth Capital Partners is acting as the sole manager for the offering.

The Company intends to use the net proceeds from the offering (including any resulting from the exercise of the warrants, if any) for general corporate purposes, including, but not limited to, funding of its clinical trials, commercialization of its products, obtaining regulatory approvals, research, capital expenditures and working capital.

The securities described above are being offered by the Company pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC"). An electronic preliminary prospectus relating to the offering will be filed with the SEC and when filed will be available on the SEC's website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, [phone] or by accessing the SEC's website, www.sec.gov.